156 related articles for article (PubMed ID: 23988418)
41. Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
Nica A; Lee JYJ; Hong NL; May T
Gynecol Oncol; 2021 Jan; 160(1):206-213. PubMed ID: 33032821
[TBL] [Abstract][Full Text] [Related]
42. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
Obata H; Yahata T; Quan J; Sekine M; Tanaka K
Anticancer Res; 2006; 26(3B):2227-32. PubMed ID: 16821592
[TBL] [Abstract][Full Text] [Related]
43. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
Moore KN; Moxley KM; Fader AN; Axtell AE; Rocconi RP; Abaid LN; Cass IA; Rose PG; Leath CA; Rutledge T; Blankenship D; Gold MA
Gynecol Oncol; 2007 Dec; 107(3):398-403. PubMed ID: 17997146
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Swanton A; Collins S; Kehoe S
Cochrane Database Syst Rev; 2007 Oct; (4):CD005343. PubMed ID: 17943850
[TBL] [Abstract][Full Text] [Related]
45. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.
Hirte H; Vergote IB; Jeffrey JR; Grimshaw RN; Coppieters S; Schwartz B; Tu D; Sadura A; Brundage M; Seymour L
Gynecol Oncol; 2006 Aug; 102(2):300-8. PubMed ID: 16442153
[TBL] [Abstract][Full Text] [Related]
46. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.
Morice P; Brehier-Ollive D; Rey A; Atallah D; Lhommé C; Pautier P; Pomel C; Camatte S; Duvillard P; Castaigne D
Ann Oncol; 2003 Jan; 14(1):74-7. PubMed ID: 12488296
[TBL] [Abstract][Full Text] [Related]
47. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI
Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660
[TBL] [Abstract][Full Text] [Related]
48. [Hyperthermic intraperitoneal chemotherapy in the treatment for recurrent ovarian cancer].
Giseĭnov KD; Beliaev AM; Senchik KIu; Maksimov SIa; Urmancheeva AF; Gafton GI; Mikaia NA; Beliaeva OA; Kireeva GS; Gorodnova TV; Matveeva NS
Vopr Onkol; 2014; 60(3):343-7. PubMed ID: 25033688
[TBL] [Abstract][Full Text] [Related]
49. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.
Shih KK; Zhou QC; Aghajanian C; Huh J; Soslow RA; Morgan JC; Iasonos A; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2010 Nov; 119(2):270-3. PubMed ID: 20719369
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
Altman AD; McGee J; May T; Lane K; Lu L; Xu W; Ghatage P; Rosen B
Gynecol Oncol; 2017 Nov; 147(2):257-261. PubMed ID: 28800940
[TBL] [Abstract][Full Text] [Related]
51. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
Kumpulainen S; Sankila R; Leminen A; Kuoppala T; Komulainen M; Puistola U; Hurme S; Hiekkanen H; Mäkinen J; Grénman S
Gynecol Oncol; 2009 Nov; 115(2):199-203. PubMed ID: 19695688
[TBL] [Abstract][Full Text] [Related]
52. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Javellana M; Hoppenot C; Lengyel E
Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
[TBL] [Abstract][Full Text] [Related]
53. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.
Gadducci A; Sergiampietri C; Guiggi I
Gynecol Endocrinol; 2013 Sep; 29(9):811-6. PubMed ID: 23767831
[TBL] [Abstract][Full Text] [Related]
54. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM; Cobb LP; Westin SN; Zhang Y; Jazaeri A; Malpica A; Sun CC
Gynecol Oncol; 2022 Nov; 167(2):139-145. PubMed ID: 36137845
[TBL] [Abstract][Full Text] [Related]
55. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study.
Barnhill DR; Kurman RJ; Brady MF; Omura GA; Yordan E; Given FT; Kucera PR; Roman LD
J Clin Oncol; 1995 Nov; 13(11):2752-6. PubMed ID: 7595734
[TBL] [Abstract][Full Text] [Related]
56. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Marth C; Abreu MH; Andersen KK; Aro KM; de Lurdes Batarda M; Boll D; Ekmann-Gade AW; Haltia UM; Hansen J; Haug AJ; Høgdall C; Korach J; Lassus H; Lindemann K; Van Nieuwenhuysen E; Ottevanger PB; Polterauer S; Schnack TH
Cancer; 2022 Aug; 128(16):3080-3089. PubMed ID: 35714310
[TBL] [Abstract][Full Text] [Related]
57. Modern chemotherapy management of recurrent ovarian cancer: a multicentre study.
Chan S; Griffin M; Stewart J; Gregory K; Hughes A; Awwad S; Allerton R; Pledge S; Thomas H; Percival F;
Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):129-34. PubMed ID: 17355109
[TBL] [Abstract][Full Text] [Related]
58. Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer.
Uysal M; Ozdogan M; Kargi A; Gunduz S; Sezgin Goksu S; Murat Tatli A; Arslan D; Mutlu H; Senol Coskun H; Bozcuk H
J BUON; 2014; 19(4):980-4. PubMed ID: 25536605
[TBL] [Abstract][Full Text] [Related]
59. Do Not Give Up.
Roux RL; Hall MR; Rustin GJS; Zweifel M
Int J Gynecol Cancer; 2017 Jul; 27(6):1060-1062. PubMed ID: 26575275
[No Abstract] [Full Text] [Related]
60. Changes in the Management and Prognosis of Ovarian Cancer Due to the New FIGO and WHO Classifications: A Case Series Observational Descriptive Study. Seven Years of Follow-up.
Gomes Ferreira M; Sancho de Salas M; González Sarmiento R; Doyague Sánchez MJ
Int J Gynecol Cancer; 2018 Oct; 28(8):1461-1470. PubMed ID: 30045138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
